Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

4/8/2014 Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen® Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen® Interaction
……Markedly Diminished Pro-Inflammatory Responses Observed in Both Non-Human Primates and in Patients with Chronic Fatigue Syndrome (CFS)


3/24/2014 Hemispherx Biopharma, Inc. Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference

3/19/2014 Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference

3/14/2014 HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2013 …Year to Year Decrease in Net Loss

3/10/2014 Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen® to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries
…New Trademarks now approved


More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com